BioWorld Asia

Sep. 25, 2002

KS Biomedix, Nycomed Sign Deal For TransMID 107 Cancer Therapy

LONDON - KS Biomedix Holdings plc agreed to a licensing deal worth up to US$60 million for its TransMID 107 brain cancer treatment with Nycomed Group. (BioWorld International) Read More

Neuro3d Raises EUR20M Privately To Fund Work In CNS Disorders

BCLC Says BRCA1 Increases Risk Of Other Cancers In Women

Modex, IsoTis Plan To Merge Programs In Orthopedics, Skin

EU Urges Use Of Biotechnology In And From Developing World

European Parliament Aims To Tighten GM Trade Rules

Eirx Pharma Formed Through Three-Way Anglo-Irish Merger

Cardion Closes EUR10M Financing To Fund CRB-15, Stem Cell Work

Acambis Completes Manufacture Of First Batch Of Smallpox Vaccine

Zentaris, Access Oncology Enter $30M Alliance For Cancer Drug

Other News To Note

Genset Shareholders Accept Bid From Serono; Integration Begins

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...